QVance’s Partnerships Driving Innovation in Advanced Therapies

NextCell Pharma AB*, parent company of QVance, proudly supports QVance’s newly announced partnership with Royale International. This collaboration, which combines Royale International’s global expertise in logistics with QVance’s innovative quality control solutions, strengthens the supply chain for cell and gene therapies across Europe.

This partnership perfectly complements QVance’s existing collaboration with bioMérieux, a global leader in diagnostic equipment and consumables. Together, these partnerships position QVance as a comprehensive service provider, bringing together top-tier solutions in both critical quality control systems and end-to-end logistics.

"At NextCell Pharma, we recognize the importance of building strong collaborations to drive the safe and reliable delivery of advanced therapies," said Dr. Mathias Svahn, CEO of NextCell Pharma AB. "With Royale International and bioMérieux as partners, QVance is uniquely positioned to address the complex needs of the cell and gene therapy sector."

The new partnership will be showcased during QVance’s launch at ATMP Sweden in Malmö today, marking an important milestone in QVance’s mission to support innovation in advanced therapies.

* NextCell Pharma AB, "NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL